An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PSMA ADC (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Progenics Pharmaceuticals
- 10 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 06 Jan 2014 New trial record